Korea Q4 Roundup: International Growth A Key Factor For Major Firms
Hanmi’s Neutropenia Drug Off To Solid US Start
Aside from record earnings reported by a number of Korean pharma companies, the industry saw a diverse range of headlines in the fourth quarter, including cross-border acquisitions and business diversification.
